The meeting is over, and the final tally is not what the first day suggested. By the close of Friday afternoon, the FDA’s Pharmacy Compounding Advisory Committee had recommended adding six of the seven peptides it reviewed to the 503A Bulks List, and had voted against one.
Emideltide, also known as delta sleep-inducing peptide or DSIP, failed on a 6 to 7 vote with one abstention. It had been proposed for insomnia, narcotic dependence, and opioid withdrawal. Epitalon cleared 7 to 5 with one abstention for insomnia. Semax cleared 8 to 5 for cerebral ischemia, migraine, and trigeminal neuralgia.
That single rejection is the genuinely new fact, and it is the most informative one, because it shows where a narrowly divided panel found the evidence too thin even in a week when it overrode FDA staff on everything else.
Why This Update Matters
For a household deciding whether to spend money on a compounded peptide, the practical question is not which way a committee voted. It is what a favorable vote actually buys you, and the honest answer is: nothing yet, and less than the marketing will claim.
The votes are recommendations. The FDA makes the final determination through notice-and-comment rulemaking, a process that commonly takes months. Nothing about a patient’s legal access changed this week.
There is also a cost consequence worth stating plainly. Compounded drugs are generally not covered by insurance, so anyone who eventually obtains these peptides through a pharmacy would pay out of pocket.
What Changed Since MedicalDaily’s Previous Report
MedicalDaily previously reported on the first day of voting, when the panel backed BPC-157, KPV, TB-500 and MOTS-C over the objections of FDA’s own scientists. At that point, three peptides remained undecided, and the panel’s overall posture was unknown.
What is different now is that the full slate is settled and the pattern is visible. FDA career staff had recommended against all seven. The committee agreed with the agency exactly once.
What We Know So Far
On the first day, BPC-157, KPV and TB-500 each passed 8 to 6 with one abstention. MOTS-C passed 7 to 5 with two abstentions. The committee held 15 voting seats for the meeting.
None of the seven peptides is part of a United States Pharmacopeia monograph or a component of an FDA-approved drug product. Most were restricted from compounding under a 2023 reclassification in which the agency said they may present significant safety risks.
FDA’s briefing materials flagged specific problems by substance, including adverse event reports following BPC-157 injection, uncertainty about carcinogenicity connected to epitalon’s mechanism, and anticoagulant and stimulant-potentiation signals for semax. On emideltide, the agency cited inadequate characterization and the potential for peptide-related impurities.
What the Committee Members Said
Speaking on the emideltide vote, FDA’s Katie Park said there is “a lack of safety and efficacy data to support using emideltide” for the proposed uses.
John Hertig, board chair of the Collaborative for Evidence-Based Medicines, told the panel during the public hearing that “there is a significant lack of evidence,” noting the most recent study he could identify was decades old.
Committee member Kevin Zacharoff, an anesthesiologist and clinical assistant professor at Stony Brook University’s Renaissance School of Medicine, explained his no vote by saying it was “impossible for me not to take FDA’s recommendations to heart” on safety and efficacy. William Zamboni, a pharmacologist at the University of North Carolina, cited a significant lack of safety data in voting against epitalon.
Members voting yes framed it differently. Pharmacist David Pope of XiFin Pharmacy Solutions said prescriber and pharmacist judgment is central to deciding whether a peptide fits a given patient. Former Puerto Rico governor Ricardo Rosselló told the panel during the open hearing that “there is a cost of doing nothing,” arguing the 2023 restrictions abandoned standards rather than raising them.
What a Compounded Preparation Is, and Is Not
This is the distinction most likely to be lost in the coming weeks.
An FDA-approved drug has cleared adequate and well-controlled trials showing it works and is acceptably safe for a defined use, and it is made in facilities the FDA inspects against manufacturing standards. A compounded preparation made under Section 503A is produced by a state-licensed pharmacy for an individual patient with a prescription, and the FDA does not review it for safety or effectiveness at all.
Adding a substance to the 503A Bulks List makes it legal to compound. It does not make it proven. And once a substance is on the list, a clinician may prescribe it outside the narrow indication the committee reviewed, so a peptide evaluated only for ulcerative colitis could be prescribed for other purposes.
Who Faces the Greatest Risk
The people most exposed are those already buying peptides from online sellers labeling them as research chemicals, where purity, sterility, and dose are unverified. Advocates for the change argue that regulated pharmacy access is safer than that market, which is a reasonable argument about relative risk rather than a claim of proven benefit.
Athletes face a distinct problem. TB-500 and MOTS-C appear on World Anti-Doping Agency prohibited lists, and a legal prescription would not prevent an anti-doping violation.
People with cancer histories, clotting disorders, or those taking anticoagulants have specific reasons to raise the FDA’s flagged concerns with a physician before considering any of these compounds.
What Remains Unknown
For every one of these seven peptides, the fundamental gap is the same: none has completed the large randomized human trials that support a standard FDA approval. Effectiveness for the proposed uses is not established. Long-term safety is not established. FDA staff also raised basic characterization questions, meaning the identity and consistency of the raw substance itself is not fully settled.
The agency has not said when it will respond to the recommendations, or whether it will accept them.
What You Can Do Now
Anyone considering these compounds should treat marketing that uses the words FDA approved as a red flag, because none of these peptides is approved and none became approved this week. Discuss any peptide use with a physician who knows your full medication list.
Do not start, stop, or change a prescribed medication based on an advisory vote. Patients currently obtaining peptides from gray-market sellers should raise that with a clinician, since product contents may not match the label.
What Happens Next
The FDA will decide whether to act on the recommendations. Any change requires proposed rulemaking with a public comment period, and observers of the process commonly estimate eight to twelve months before legality is unambiguous. The public docket for this meeting remains the place where written comments were filed. MedicalDaily will track the agency’s formal response.
The Bottom Line
The newest confirmed fact is that the panel finished by rejecting emideltide 6 to 7 while backing six other peptides, all against FDA staff recommendations. The people most affected are patients already using or considering these compounds, and the most reasonable step is a conversation with a physician rather than a purchase. The central uncertainty is whether the FDA follows a committee it has occasionally overruled before, and the next development is the agency’s formal response.
Developing Story Timeline
July 24, 2026: The committee rejects emideltide 6 to 7 with one abstention, recommends epitalon 7 to 5 and semax 8 to 5, closing the meeting with six of seven peptides endorsed.
July 23, 2026: The committee recommends BPC-157, KPV, and TB-500 at 8 to 6 with one abstention, and MOTS-C at 7 to 5 with two abstentions.
April 15, 2026: FDA publishes the Federal Register notice announcing the two-day meeting and opening the public docket.
2023: FDA reclassification restricts compounding of these peptides, citing potential significant safety risks.
